Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label multiple-session study of miridesap + dezamizumab for systemic amyloidosis
2016-000276-23Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of miridesap and dezamizumab in systemic amyloidosis, sponsored by GSK. Primary endpoint: Change in LV mass over time from baseline to 8-week follow-up. Started Jul 2016; status: completed.
02
Drugs
miridesapdezamizumab
03
Conditions
systemic amyloidosis
Beyond the preview
Go deeper on 2016-000276-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000276-23.